DISHMAN CARBOGEN AMCIS LIMITED

ISIN: INE385W07059

YTM Icon10.35%
YTM
₹ 91,444.59
Min Investment
Quarterly
Payout
₹ 1,00,000
Face Value
10.00%
Coupon
20 Jan 2029
Maturity Date
Currently subscribedLot Size : 50 Units available
0% Completed

Interest Calculator

InterestQuarterly
InterestQuarterly

Sign up to view detailed payout schedule

About The Issuer

Dishman Carbogen Amcis Limited (DCAL) is a globally integrated CRAMS (Contract Research & Manufacturing Services) and specialty chemicals company serving innovator and generic pharmaceutical clients. The group offers end-to-end services across process R&D, scale-up, late-stage clinical and commercial manufacturing, including APIs, intermediates, high-potency APIs and Vitamin-D analogues. DCAL operates manufacturing and R&D facilities across India, Europe and other global locations through the Carbogen Amcis network and supplies to regulated markets.

Metric
FY23
Revenue (₹ cr)
2,412.9
Net Worth (₹ cr)
~5,810
EBITDA (₹ cr)
414.2 (Adj.)
PAT (₹ cr)
Moderated
Rating
IND A+/Stable
💡Issuer Health Summary

Key financial indicators to assess stability & repayment capacity.

Key Risks & Disclosures

Regulatory & Compliance Risk:DCAL’s European facilities have faced regulatory observations from EDQM in recent years, impacting production and profitability. Any adverse regulatory outcomes can affect exports, revenues and cash flows.
Client & Product Concentration:A meaningful share of revenues is driven by marketable molecules (vitamin D analogues, specialty chemicals). Demand cyclicality in pharma and pricing pressure in generics can impact earnings.
Global Operating Cost Volatility:High energy costs in Europe, currency volatility and compliance capex can materially affect margins and near-term profitability.
Project Execution & R&D Risk:CRAMS pipeline execution depends on successful scale-up and regulatory approvals of client molecules. Delays in client programs can lead to volatility in capacity utilisation.

Invest

Trade & Settlement

Trade date
10 Apr 2026
Orders placed after 4 PM will be executed on the next business day.Weekends & exchange holidays are skipped.

Totals (For Selected Units)

Price per Unit
₹99,757.73
Investment amount
₹99,757.73
Total Interest
₹15,007.48
Total Receivable
₹1,15,007.48

Download Diligence Documents

Consent letter from DT 10.12.2025_20260120211756Download
NCD Rating Letter_20260120211756Download
Disclosure DocumentsDownload
KEY INFORMATION DOCUMENTDownload
Annexure V Shareholding Structure for quarter ended 30 09 2025Download
Annexure II Related Party TransactionsDownload
Annexure III ResolutionsDownload
Annexure VII Peer Review CertificateDownload
GENERAL INFORMATION DOCUMENTDownload
Equirize Logo

EquiRize Securities Private Limited.

Legal & Compliance

Investor Charter Regulatory Disclosures Policies & Procedures Grievance Redressal Mechanism

Quick Links

Privacy Policy Terms & Conditions Investor Complaints

Help

Contact UsSitemap

Registered Office: 301 Chawla Complex Commercial Premises, Sector 15, CBD Belapur, Navi Mumbai 400614 Maharashtra

© 2025 EquiRize. All rights reserved. | CIN: U66190MH2024PTC430982 | SEBI Registration Number (Stock Broker): INZ000323730 | BSE Membership No. 6914 - Debt Segment | NSE Membership No. 90472 - Debt Segment

Compliance Officer:

Srilakshmi Deshmukh

compliance@EquiRize.com, +91-7993739228

Investor Protection Guidelines:

  1. Prevent Unauthorised Transactions:
    • Update your mobile number and email ID with your Stock Broker and Depository Participant.
    • Receive transaction alerts directly from the Exchange and NSDL/CDSL the same day.
  2. IPO Application Process:
    • No need to issue a cheque. Mention your bank account number and sign the IPO application form to authorise payment via ASBA.
    • In case of non-allotment, funds remain in your bank account.
  3. KYC Compliance:
    • KYC is a one-time process. Once completed with a SEBI-registered intermediary (broker, DP, mutual fund, etc.), it is valid across all intermediaries.
  4. Stay Vigilant:
    • Beware of fraudsters sending bulk messages with fake investment tips or promises of guaranteed returns.
    • Do not engage in unauthorised portfolio management or collective investment schemes promising fixed/guaranteed returns.

Important Note: Fixed Deposits (FDs) and Peer to Peer (P2P) Lending are not exchange-traded products. EquiRize Securities solely connects investors/lenders with said products.

Digital Accessibility

We are committed to ensuring that our digital platforms are accessible to all users, including persons with disabilities, in line with applicable SEBI guidelines.

For any accessibility-related assistance or concerns, please contact:

Nodal Officer – Digital Accessibility

Name: Mohit Gupta

Designation: Director

Email: accessibility@equirize.com

Contact: +91 9818544346

Attention Investors:

  • Stock Brokers can accept securities as margin only through pledge in the depository system (w.e.f. September 1, 2020).
  • Ensure your contact details are updated to receive OTPs directly from NSDL/CDSL for pledge creation.
  • Review your holdings regularly via the Consolidated Account Statement issued monthly by NSDL/CDSL.

Useful Links:

SEBI: https://www.sebi.gov.in

NSDL: https://www.nsdl.co.in

CDSL: https://www.cdslindia.com

NSE: https://www.nseindia.com

BSE: https://www.bseindia.com

SCORES 2.0: https://scores.sebi.gov.in

SMART ODR Portal: https://smartodr.in/login

Issued in the interest of investors by EquiRize Securities Private Limited.